NANOBIOTIX to Present Four Posters Including Updates From Priority Head and Neck Cancer and Immunotherapy Development Pathways at the 2021 Annual Meeting of the American Society for Clinical Oncology
(1) New data with additional patients and further follow up from Study 1100, evaluating lead product candidate NBTXR3 in combination with anti-PD-1 in head and neck cancer, lung metastasis and/or liver metastasis New data with additional patients and further follow up on safety and response rate from Study 102 dose expansion, evaluating NBTXR3 as a single agent activated by radiotherapy in head and neck cancer Long term safety data from complete European phase II/III registration study, Act.In.Sarc, evaluating NBTXR3 as a single agent activated by radiotherapy in soft tissue sarcoma "From ben...